NCT04224051View on ClinicalTrials.gov

Metformin for Abdominal Aortic Aneurysm Growth Inhibition

PHASE2Enrolling by invitationINTERVENTIONAL
Enrollment

500

Participants

Timeline

Start Date

February 12, 2020

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions
Abdominal Aortic Aneurysm
Interventions
DRUG

Metformin

Metformin target dose 2 g daily

OTHER

Standard care

Abdominal aortic aneurysm surveillance

Trial Locations (1)

Unknown

Uppsala University Hospital, Uppsala

All Listed Sponsors
lead

Uppsala University Hospital

OTHER